SCHEMBL6468049

SCHEMBL6468049

COCCN1CCN([C@H]2CC[C@@H](n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCK P08631 11/20 0.83
▸ LCK P06239 9/20 0.79
▸ SRC P12931 9/20 0.79
▸ TEK Q02763 8/20 0.79
▸ FLT3 P36888 6/20 0.79
▸ KDR P35968 4/20 0.79
▸ BTK Q06187 4/20 0.79
▸ EGFR P00533 2/20 0.79
▸ FYN P06241 2/20 0.79
▸ LYN P07948 2/20 0.79
▸ CSK P41240 2/20 0.79
▸ PRKD3 O94806 2/20 0.79
▸ PRKCD Q05655 2/20 0.79
▸ PLK4 O00444 1/20 0.79
▸ DCLK1 O15075 1/20 0.79
▸ PDPK1 O15530 1/20 0.79
▸ MAP4K4 O95819 1/20 0.79
▸ PAK4 O96013 1/20 0.79
▸ CHEK2 O96017 1/20 0.79
▸ ABL1 P00519 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6461460 1.00 HCK (0.83) HCKLCKSRCTEKFLT3
SCHEMBL6461457 1.00 HCK (0.83) HCKLCKSRCTEKFLT3
Fumaric Acid SCHEMBL6465398 0.94 HCK (0.76) HCKLCKSRCTEKFLT3
Maleic Acid SCHEMBL6465396 0.94 HCK (0.76) HCKLCKSRCTEKFLT3
Maleic Acid SCHEMBL6467937 0.94 HCK (0.76) HCKLCKSRCTEKFLT3
Fumaric Acid SCHEMBL6467943 0.94 HCK (0.76) HCKLCKSRCTEKFLT3
SCHEMBL16752469 0.91 HCK (1.00) HCKLCKSRCTEKFLT3
SCHEMBL16752471 0.91 HCK (1.00) HCKLCKSRCTEKFLT3
SCHEMBL22845563 0.90 HCK (0.80) HCKLCKSRCTEKFLT3
SCHEMBL22845296 0.90 HCK (0.80) HCKLCKSRCTEKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US claimed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US claimed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US disclosed
CN-1335849-A Pyrrolopyrimidines as protein kinase inhibitors BASF AG (DE) 2002-02-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN HCK 107/4885LCK 1/4885SRC 46/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI HCK 968/4885LCK 6/4885SRC 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback